Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.

TitleOntology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.
Publication TypeJournal Article
Year of Publication2012
AuthorsSarntivijai, Sirarat, Xiang Zuoshuang, Shedden Kerby A., Markel Howard, Omenn Gilbert S., Athey Brian D., and He Yongqun
JournalPLoS One
Volume7
Issue11
Paginatione49941
Date Published2012
ISSN1932-6203
KeywordsHumans, Influenza Vaccines, Influenza, Human, Vaccines, Attenuated, Vaccines, Inactivated
Abstract

Vaccine adverse events (VAEs) are adverse bodily changes occurring after vaccination. Understanding the adverse event (AE) profiles is a crucial step to identify serious AEs. Two different types of seasonal influenza vaccines have been used on the market: trivalent (killed) inactivated influenza vaccine (TIV) and trivalent live attenuated influenza vaccine (LAIV). Different adverse event profiles induced by these two groups of seasonal influenza vaccines were studied based on the data drawn from the CDC Vaccine Adverse Event Report System (VAERS). Extracted from VAERS were 37,621 AE reports for four TIVs (Afluria, Fluarix, Fluvirin, and Fluzone) and 3,707 AE reports for the only LAIV (FluMist). The AE report data were analyzed by a novel combinatorial, ontology-based detection of AE method (CODAE). CODAE detects AEs using Proportional Reporting Ratio (PRR), Chi-square significance test, and base level filtration, and groups identified AEs by ontology-based hierarchical classification. In total, 48 TIV-enriched and 68 LAIV-enriched AEs were identified (PRR>2, Chi-square score >4, and the number of cases >0.2% of total reports). These AE terms were classified using the Ontology of Adverse Events (OAE), MedDRA, and SNOMED-CT. The OAE method provided better classification results than the two other methods. Thirteen out of 48 TIV-enriched AEs were related to neurological and muscular processing such as paralysis, movement disorders, and muscular weakness. In contrast, 15 out of 68 LAIV-enriched AEs were associated with inflammatory response and respiratory system disorders. There were evidences of two severe adverse events (Guillain-Barre Syndrome and paralysis) present in TIV. Although these severe adverse events were at low incidence rate, they were found to be more significantly enriched in TIV-vaccinated patients than LAIV-vaccinated patients. Therefore, our novel combinatorial bioinformatics analysis discovered that LAIV had lower chance of inducing these two severe adverse events than TIV. In addition, our meta-analysis found that all previously reported positive correlation between GBS and influenza vaccine immunization were based on trivalent influenza vaccines instead of monovalent influenza vaccines.

DOI10.1371/journal.pone.0049941
Alternate JournalPLoS ONE
PubMed ID23209624
PubMed Central IDPMC3509157
Grant ListR01AI081062 / AI / NIAID NIH HHS / United States
U54 DA021519 / DA / NIDA NIH HHS / United States
U54 HG004028 / HG / NHGRI NIH HHS / United States